comparemela.com
Home
Live Updates
Next-Generation Cologuard® Test Demonstrates High Sensi
Next-Generation Cologuard® Test Demonstrates High Sensi
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the...
Related Keywords
United States ,
American ,
Setha Gross ,
Thomasf Imperiale ,
Megan Jones ,
Paul Limburg ,
Lindsey Dickinson ,
Prnewswire Exact Sciences Corp ,
Us Preventive Services Task ,
Grossman School Of Medicine ,
Genomic Health Inc ,
Facebook ,
American Joint Committee On Cancer Staging System ,
Sciences Corp ,
Exchange Commission ,
Linkedin ,
American College Of Gastroenterology ,
Twitter ,
National Comprehensive Cancer Network ,
American Cancer Society ,
Sciences Corporation ,
Nasdaq ,
Regenstrief Institute ,
United States Census Bureau ,
Indiana University School Of Medicine ,
American College ,
Annual Meeting ,
American Joint Committee ,
Cancer Staging System ,
Indiana University School ,
Analysis Presented ,
Supports Performance ,
Next Generation Cologuard ,
Exact Sciences ,
Mayo Clinic ,
Exact Science ,
New England Journal ,
Services Task Force ,
Genomic Health ,
Risk Factors ,
Annual Report ,
Quarterly Reports ,
States Census ,
Annual Estimates ,
Resident Population ,
Single Year ,
Exact Sciences Corp ,